Abstract
To date a total of 640 patients have been registered in the Intergroup Rhabdomyosarcoma Study. Twelve early deaths have been reported. All occurred within 34 days of the start of therapy. Five had pharyngeal primaries and 2 had primaries in the maxillary sinus - all seven had Group III disease (gross residual disease). Most fatalities were associated with granulocytopenia and thrombocytopenia. Four fatalities were associated with membranous colitis at autopsy.
Forty-seven of 417 evaluable patients (11%) developed hematuria. The hematuria was moderate or severe in 80% of cases. It occurred with equal frequency throughout treatment and occurred for the first time in some patients after therapy was stopped. Severe neutropenia (<500/mm3) was observed in 67% of patients in Regimen E and 72% of patients in Regimen F (Clinical Groups III and IV). Adriamycin cardiomyopathy has not been observed in this study.
Since most early deaths occurred in patients with head and neck primaries, the use of less intensive initial chemotherapeutic regimens may be advisable for these patients.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ragab, A., Donaldson, M., Moon, T. et al. 650 TOXICITY IN THE INTERGROUP RHABDOMYOSARCOMA STUDY(IRS): A PRELIMINARY REPORT. Pediatr Res 12 (Suppl 4), 472 (1978). https://doi.org/10.1203/00006450-197804001-00655
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-00655